Point-of-care blood cell count through micro-ELISA

通过微量 ELISA 进行即时血细胞计数

• 批准号: 131948
• 金额: $ 2.94万
• 依托单位: ORPHIDIA LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131948
• 关键词: Point; care; blood; cell; count

Orphidia is developing the first ever point of care blood test device that offers measurement of up to 50 health indicators at laboratory accuracy, with results provided within 30 minutes. In this project we will extend our current technology from protein biomarker measurement to blood cell count, opening up the use of our device for new diagnostic purposes such as HIV/AIDS screening or differentiation between bacterial and viral infections. During the project we will show that our innovative measurement gives the right result, first from a laboratory analogue of a blood sample and then from a real blood sample (donated by the researchers themselves). The project will prove the Principle of our measurement and will identify the steps for further development needed to bring this technology to market (which we expect to happen approximately 2 years after completion of the current project). Successful delivery of this project will grow our R&D activities and accelerate commercial roll-out of our first product to the human or veterinary diagnostic market.

Orphidia正在开发有史以来第一个即时血液检测设备，该设备可以在实验室准确度下测量多达50项健康指标，并在30分钟内提供结果。在这个项目中，我们将把我们目前的技术从蛋白质生物标志物测量扩展到血细胞计数，从而将我们的设备用于新的诊断目的，如艾滋病毒/艾滋病筛查或区分细菌和病毒感染。在该项目中，我们将展示我们的创新测量方法可以给出正确的结果，首先是实验室模拟的血液样本，然后是真实的血液样本（由研究人员自己捐赠）。该项目将证明我们的测量原理，并将确定将该技术推向市场所需的进一步开发步骤（我们预计将在当前项目完成后约2年内实现）。该项目的成功交付将促进我们的研发活动，并加速我们的第一个产品在人类或兽医诊断市场的商业推广。